Our Story
Enabling Immunity
The AbelZeta Difference
Our goal is to rapidly advance innovative T cell immunotherapies by leveraging proof-of-concept data from early-stage clinical trials. This approach enables informed decision-making promptly, enhancing the overall success of drug development. Clinical data is essential for understanding performance for this new class of cell-based immunotherapies.
AbelZeta has endeavored to test drug candidates as fast as possible in investigator-initiated trials in order to de-risk and improve the efficiency of the drug candidate selection process.
Core Strengths
Proven Target & Optimal Design
Pipeline assets optimized internally by maximizing specificity while minimizing toxicity.
Exceptional Early Clinical Results
Early clinical data showed best-in-class and best-in-disease potential for multiple assets.
Partnered Lead Program
Partnerships with global pharma for hematological cancer & solid tumors to leverage their strong expertise in clinical development and global commercialization.
Platform Potential
In-house platform established to facilitate the development of multiple cell therapies to target both cancer and I&I diseases.